Testosterone News and Research

Latest Testosterone News and Research

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

BioSante Pharmaceuticals, Inc. will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.

30 Apr 2010

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Antares Pharma, Inc., a leader in self-injection drug delivery technology and Uman Pharma, a manufacturer of top-quality injectable pharmaceutical products based in Quebec, Canada, today announced the formation of a strategic alliance covering Antares' VIBEX™ MTX.

27 Apr 2010

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Research presented at the European Congress of Endocrinology shows for the first time that men with erectile dysfunction and low testosterone have a higher than normal risk of dying from cardiovascular disease. Further work from the same research group shows that obesity is also associated with an impairment of blood flow to the penis, which in turn is also associated with cardiovascular disease in men with erectile dysfunction.

27 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

CPEX recommends shareholders to take no action on Arcadia's unsolicited tender offer

The Board of Directors of CPEX Pharmaceuticals Inc., today recommended that its shareholders take no action at this time in response to the announcement by Arcadia Capital Advisors, LLC through RSR Acquisition Co. and its principal Richard Rofé that it has made an unsolicited conditional tender offer to acquire all of the outstanding shares of CPEX for $16.00 per share in cash.

24 Apr 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.

23 Apr 2010

Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36%

Columbia Laboratories, Inc. today announced preliminary results for the quarter ended March 31, 2010.

22 Apr 2010

Lipocine announced receipt of $2M development milestone payment from Abbott

Lipocine Inc. announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone.

21 Apr 2010

Calorie restriction may help people to lead longer and healthier lives

Organisms from yeast to rodents to humans all benefit from cutting calories. In less complex organisms, restricting calories can double or even triple lifespan. It's not yet clear just how much longer calorie restriction might help humans live, but those who practice the strict diet hope to survive past 100 years old.

16 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Risks and benefits of anti-aging hormones

In an editorial appearing in the Future Medicine journal Aging Health, Dr. Perls applauds the courage and example displayed by the AMA in its recently published assessment of the risks and benefits of growth hormone, testosterone, estrogen and DHEA for anti-aging.

15 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

Hormones leptin and insulin work together to affect regulation of blood sugar levels, female fertility

New findings by UT Southwestern Medical Center researchers suggest that the hormones leptin and insulin work together in specific neurons in the hypothalamus region of the brain to affect both the regulation of blood sugar levels in the body and, surprisingly, female fertility.

12 Apr 2010

Whey Protein Isolate damages and accelerates hair loss

Dr. Larry Shapiro, a nationally recognized hair transplant surgeon and dermatologist in South Florida, announced today the results of a study that compared the Effects of Whey Protein Concentrate (WPC) to Whey Protein Isolate (WPI) on Hair, which suggests that WPI, an ingredient found in many popular weight loss, meal replacement and body building products, is contributing to hair loss.

8 Apr 2010

Fireside chat: BioSante's LibiGel and GVAX cancer vaccines portfolio

BioSante Pharmaceuticals, Inc. today announced that a BioSante presentation and corporate discussion are available at http://www.rodm.tv/video1269553400.

3 Apr 2010

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Healthy pre-and post-menopausal Japanese women who took a supplement of SE5-OH containing Natural S-equol, a novel soy germ-based ingredient under development for the management of menopausal symptoms, had measures of reproductive hormones that stayed within normal limits throughout the study.

3 Apr 2010

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

CPEX Pharmaceuticals Inc. today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX's patented intranasal drug delivery technology.

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Athletes and ethicists look at fairness in sport

Just in time for baseball’s opening day, a series of articles in the Hastings Center Report asks what constitutes fairness in elite sports and what it takes to stop cheating. New issues, including the prospect of gene doping and questions about which athletes are really “female,” are explored.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Testosterone News and Research

Latest Testosterone News and Research

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

CPEX recommends shareholders to take no action on Arcadia's unsolicited tender offer

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36%

Lipocine announced receipt of $2M development milestone payment from Abbott

Calorie restriction may help people to lead longer and healthier lives

Targeted therapy MDV3100 is effective for patients with CRPC: Study

Risks and benefits of anti-aging hormones

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

Hormones leptin and insulin work together to affect regulation of blood sugar levels, female fertility

Whey Protein Isolate damages and accelerates hair loss

Fireside chat: BioSante's LibiGel and GVAX cancer vaccines portfolio

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

Athletes and ethicists look at fairness in sport

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Testosterone News and Research

Latest Testosterone News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in